CADL vs. XERS, ABCL, EVO, COLL, NTLA, CVAC, ELVN, CALT, SPRY, and PHVS
Should you be buying Candel Therapeutics stock or one of its competitors? The main competitors of Candel Therapeutics include Xeris Biopharma (XERS), AbCellera Biologics (ABCL), Evotec (EVO), Collegium Pharmaceutical (COLL), Intellia Therapeutics (NTLA), CureVac (CVAC), Enliven Therapeutics (ELVN), Calliditas Therapeutics AB (publ) (CALT), ARS Pharmaceuticals (SPRY), and Pharvaris (PHVS). These companies are all part of the "pharmaceutical products" industry.
Candel Therapeutics vs. Its Competitors
Xeris Biopharma (NASDAQ:XERS) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, analyst recommendations, profitability, institutional ownership and risk.
Candel Therapeutics has a net margin of 0.00% compared to Xeris Biopharma's net margin of -13.01%. Xeris Biopharma's return on equity of 0.00% beat Candel Therapeutics' return on equity.
Xeris Biopharma currently has a consensus target price of $7.08, suggesting a potential downside of 7.77%. Candel Therapeutics has a consensus target price of $20.00, suggesting a potential upside of 302.41%. Given Candel Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Candel Therapeutics is more favorable than Xeris Biopharma.
In the previous week, Xeris Biopharma had 1 more articles in the media than Candel Therapeutics. MarketBeat recorded 13 mentions for Xeris Biopharma and 12 mentions for Candel Therapeutics. Xeris Biopharma's average media sentiment score of 1.21 beat Candel Therapeutics' score of 0.26 indicating that Xeris Biopharma is being referred to more favorably in the media.
Xeris Biopharma has a beta of 0.12, meaning that its share price is 88% less volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of -0.9, meaning that its share price is 190% less volatile than the S&P 500.
42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 4.6% of Xeris Biopharma shares are held by company insiders. Comparatively, 16.6% of Candel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Xeris Biopharma has higher revenue and earnings than Candel Therapeutics. Xeris Biopharma is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Xeris Biopharma beats Candel Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Candel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CADL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Candel Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CADL) was last updated on 9/9/2025 by MarketBeat.com Staff
Free CADL Stock Alerts